ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc (CLDI)

0.195
-0.009
(-4.41%)
Closed June 17 4:00PM
0.201
0.006
( 3.08% )
Pre Market: 6:48AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.201
Bid
-
Ask
-
Volume
85,955
0.00 Day's Range 0.00
0.1435 52 Week Range 5.00
Market Cap
Previous Close
0.195
Open
-
Last Trade
5
@
0.2093
Last Trade Time
06:46:28
Financial Volume
-
VWAP
-
Average Volume (3m)
2,056,192
Shares Outstanding
35,492,403
Dividend Yield
-
PE Ratio
-0.23
Earnings Per Share (EPS)
-0.82
Revenue
-
Net Profit
-29.22M

About Calidi Biotherapeutics Inc

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Calidi Biotherapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CLDI. The last closing price for Calidi Biotherapeutics was $0.20. Over the last year, Calidi Biotherapeutics shares have traded in a share price range of $ 0.1435 to $ 5.00.

Calidi Biotherapeutics currently has 35,492,403 shares outstanding. The market capitalization of Calidi Biotherapeutics is $6.74 million. Calidi Biotherapeutics has a price to earnings ratio (PE ratio) of -0.23.

CLDI Latest News

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to...

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi’s best-in-class, novel systemic targeted virotherapy program (RTNova) aims to provide a feasible solution to target disseminated tumors with a systemic administration -- a long-pursued...

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

- NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses of CLD-101 - Showcased preclinical data on RTNova (CLD-400...

 Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the...

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program, to be presented at 2024 ASCO Annual Meeting Presented new data on the mechanisms of action of...

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the acceptance of...

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to invite investors to a webinar on...

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0010.50.20.270.187520990030.24258458CS
4-0.052-20.55335968380.2530.490.180134399790.22537986CS
12-0.375-65.10416666670.5760.830.143520561920.25232522CS
26-1.819-90.04950495052.022.040.143510788550.33818024CS
52-4.309-95.54323725064.5150.14357248420.40776722CS
156-4.309-95.54323725064.5150.14357248420.40776722CS
260-4.309-95.54323725064.5150.14357248420.40776722CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NLSPNLS Pharmaceutics Ltd
$ 0.465
(213.55%)
53.05M
ASNSActelis Networks Inc
$ 2.31
(100.87%)
5.47M
DYNTDynatronics Corp
$ 0.60
(65.75%)
5
MBIOMustang Bio Inc
$ 0.983
(31.07%)
20.45M
MLGOMicroAlgo Inc
$ 4.54
(27.89%)
1.31M
AWINAERWINS Technologies Inc
$ 1.52
(-54.49%)
22.18k
QMCOQuantum Corporation
$ 0.4659
(-40.27%)
37.14k
BIOLBiolase Inc
$ 0.1047
(-29.54%)
3.46M
AAGRAfrican Agriculture Holdings Inc
$ 0.2407
(-27.50%)
3
YYAIConnexa Sports Technologies Inc
$ 0.414
(-24.01%)
91.62k
NLSPNLS Pharmaceutics Ltd
$ 0.465
(213.55%)
53.05M
MBIOMustang Bio Inc
$ 0.983
(31.07%)
20.45M
ASNSActelis Networks Inc
$ 2.31
(100.87%)
5.47M
QLGNQualigen Therapeutics Inc
$ 0.1805
(3.26%)
5.42M
SNOASonoma Pharmaceuticals Inc
$ 0.1924
(14.18%)
3.61M

Your Recent History

Delayed Upgrade Clock